CStone Pharmaceuticals (FRA:PH4)

Market Cap	921.84M
Revenue (ttm)	24.07M
Net Income (ttm)	-44.82M
Shares Out	n/a
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2
Average Volume	278
Open	0.6400
Previous Close	0.6050
Day's Range	0.6200 - 0.6400
52-Week Range	0.2300 - 1.3500
Beta	n/a
RSI	44.20
Earnings Date	Nov 20, 2025

About CStone Pharmaceuticals

CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, and relapsed or refractory natural killer/T cell lymphoma; GAVRETO (pralsetinib), a RET inhibitor...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Employees: 135
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: PH4

Financial Performance

In 2024, CStone Pharmaceuticals's revenue was 407.21 million, a decrease of -12.21% compared to the previous year's 463.84 million. Losses were -91.21 million, -75.16% less than in 2023.

Financial numbers in CNY